Yasmine MD - Savara Senior Development
| SVRA Stock | USD 3.36 0.11 3.17% |
Executive
Yasmine MD is Senior Development of Savara Inc
| Address | 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047 |
| Phone | 512 614 1848 |
| Web | https://www.savarapharma.com |
Savara Management Efficiency
The company has return on total asset (ROA) of (0.2639) % which means that it has lost $0.2639 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4796) %, meaning that it created substantial loss on money invested by shareholders. Savara's management efficiency ratios could be used to measure how well Savara manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.34. The current year's Return On Capital Employed is expected to grow to -0.34. At present, Savara's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 458 K, whereas Non Current Assets Total are forecasted to decline to about 11.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shelly Pinto | Alx Oncology Holdings | 47 | |
| Tracey MBA | Scholar Rock Holding | 48 | |
| James MD | AnaptysBio | 62 | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Kevin Healy | Entrada Therapeutics | N/A | |
| Lisa Sauer | Alx Oncology Holdings | N/A | |
| Daniel Wilson | Dyne Therapeutics | 52 | |
| Lisa Price | Scholar Rock Holding | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Joe Tedrick | Kezar Life Sciences | N/A | |
| Beth Mueller | AnaptysBio | N/A | |
| Priya Raina | AnaptysBio | N/A | |
| Christiana MBA | Fennec Pharmaceuticals | N/A | |
| Athanasios MD | Alx Oncology Holdings | N/A | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| Douglas MBA | AnaptysBio | 55 | |
| Gopal MBBS | Rezolute | N/A | |
| Chadwick MPH | Longboard Pharmaceuticals | N/A | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Lucia Celona | Dyne Therapeutics | 58 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.26 |
Savara Inc Leadership Team
Elected by the shareholders, the Savara's board of directors comprises two types of representatives: Savara inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Savara. The board's role is to monitor Savara's management team and ensure that shareholders' interests are well served. Savara's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Savara's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anne Erickson, IR Contact Officer | ||
| Matthew Pauls, Independent Director | ||
| MBA JD, Chairman CEO | ||
| Peter Clarke, Executive Operations | ||
| David CPA, Chief CFO | ||
| Brian Maurer, Head Operations | ||
| Charles LaPree, Senior Assurance | ||
| Yasmine MD, Senior Development | ||
| Kate JD, Senior Counsel | ||
| Robert MBA, Chief Officer | ||
| Brian MD, Senior Affairs | ||
| Kate McCabe, Senior Counsel | ||
| MD FACP, Chief Officer | ||
| Scott Wilhoit, Executive Commercial |
Savara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Savara a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 383.91 M | ||||
| Shares Outstanding | 171.62 M | ||||
| Shares Owned By Insiders | 4.59 % | ||||
| Shares Owned By Institutions | 96.93 % | ||||
| Number Of Shares Shorted | 13 M | ||||
| Price To Earning | (2.46) X | ||||
| Price To Book | 2.89 X | ||||
| Price To Sales | 131,146 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Savara Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Savara's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Savara Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Savara Inc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Savara Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Savara. If investors know Savara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Savara listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.43) | Return On Assets (0.26) | Return On Equity (0.48) |
The market value of Savara Inc is measured differently than its book value, which is the value of Savara that is recorded on the company's balance sheet. Investors also form their own opinion of Savara's value that differs from its market value or its book value, called intrinsic value, which is Savara's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Savara's market value can be influenced by many factors that don't directly affect Savara's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Savara's value and its price as these two are different measures arrived at by different means. Investors typically determine if Savara is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Savara's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.